NDAORAL-21TABLETPriority Review
Approved
May 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO TRI-CYCLEN 21 is an oral contraceptive containing ethinyl estradiol and norgestimate in a 21-day tablet formulation. It prevents pregnancy through hormonal suppression of ovulation and alteration of cervical mucus. This combination oral contraceptive is one of the most widely prescribed birth control options globally.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing and shift toward market defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings signal minimal active hiring around ORTHO TRI-CYCLEN 21, consistent with LOE approaching lifecycle stage. Career opportunities on this product are limited to defensive brand management, compliance, and existing team transitions.
Brand ManagerField Sales Representative
Worked on ORTHO TRI-CYCLEN 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.